title: Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
authors.forename: A
authors.initials: A
authors.lastname: Alimonti
authors.forename: G
authors.initials: G
authors.lastname: Ferretti
authors.forename: S
authors.initials: S
authors.lastname: Di Cosimo
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
authors.forename: A
authors.initials: A
authors.lastname: Vecchione
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D005467:Floxuridine / Q000008:administration & dosage*; D005472:Fluorouracil / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D011379:Prognosis; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; D013940:Thymidylate Synthase; D005472:Fluorouracil